Important Notice
This annual report is a summary of the full annual report, aimed at providing an understanding of the company's overall development, financial status, and future growth plans. Investors are advised to refer to the complete annual report.
All matters discussed herein are subject to the following considerations.
The company has not made any significant changes to its business operations.
The company’s total share capital is expected to reach 2,212,441,394 shares by December 31, 2025.
Every 10 shares will be priced at 3.10 yuan (tax included), excluding the company's capital increase.
The company has proposed the following profit distribution plan for the upcoming period:
| Proposal | Not Applicable |
|---|---|
| The company has achieved operating income of 3,328,215.94 million yuan, a decrease of 9.38% compared to the previous year, with a net profit of 845,147.14 million yuan, a decrease of 30.28%. | |
| In the domestic market, the company achieved operating income of 1,765,037.52 million yuan, an increase of 7.40%. The proportion of international business income has further increased by 53%. |
Company Overview
Company Introduction
| Stock Name | Mindray Medical |
|---|---|
| Stock Code | 300760 |
| Trading Place | Shenzhen Stock Exchange |
| Major Business | Medical Devices |
Contact Person and Contact Method
| Name | Li Wenxian |
|---|---|
| Position | Chairman |
| Contact Number | 0755-26582860 ext. 8398 |
| ir@mindray.com |
Main Business or Product Introduction
- The main business of the company
2025 marks the year of the "14th Five-Year Plan," which is a further step towards comprehensive reform. As the world continues to accelerate its development, the medical industry is facing significant changes. The company aims to enhance its core competitiveness through innovation and digital transformation, thereby improving service quality and efficiency.
The company is committed to "maintaining the core competitiveness of the industry" and will continue to innovate in human-centered services. We believe that technology will play a crucial role in enhancing the efficiency of healthcare services.
The company has achieved operating income of 3,328,215.94 million yuan, with a net profit of 845,147.14 million yuan, reflecting a decrease compared to the previous year.
Business Performance
The company’s main business achieved operating income of 1,224,065.69 million yuan, a decrease of 9.41%. The external diagnostic business accounted for over 36% of total revenue, with the second year being the largest segment.
In the domestic market, the company achieved operating income of 1,163,178.42 million yuan, a decrease of 19.80%.
Business Development and Future Outlook
The company will continue to enhance its core business capabilities and expand its market share. It aims to leverage digital transformation to improve operational efficiency and service quality.
The company is focused on maintaining its competitive edge in the global market while adapting to changes in domestic and international environments.
Business Development and Strategy
As of December 31, 2025, the company will have established partnerships with 30 hospitals, including Zhejiang University Medical College First Affiliated Hospital, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, and others. The company aims to expand its smart medical assistance system and core medical technology, with a focus on integrating AI technology into its services.
The key features of the model include: 1) Clinical monitoring that can assess patient conditions within 5 seconds, providing insights for 24-hour patient monitoring; 2) Enhanced knowledge and policy recommendations based on 95% accuracy in analyzing patient data; 3) Automatic identification of work efficiency, with a goal of reducing hospital-acquired infections by over 70% and increasing patient admission rates by over 50%.